<DOC>
	<DOCNO>NCT00484289</DOCNO>
	<brief_summary>The purpose study demonstrate safety chronic use abatacept Japanese Subjects Rheumatoid Arthritis ( RA ) complete clinical study IM101-071 , IM101-034 , also Disease Modifying Anti-Rheumatic Drugs ( DMARDs ) failures MTX intolerance .</brief_summary>
	<brief_title>A Phase III Study Abatacept Japanese Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Inclusion Criteria The participant complete 169 day , full study period Phase II ( IM101071 ) administer biologics completion IM101071 registration longterm study . The participant Phase I study ( IM101034 ) , receive abatacept , except participant withdraw study due safety problem related abatacept . New subject MTX intolerance : rheumatoid arthritis ( RA ) patient MTX administer safety reason present inadequate response diseasemodifying antirheumatic drug ( DMARDs ; exclude MTX ) biologics ( new subject MTX intolerance : RA patient present inadequate response DMARDs ) . Exclusion Criteria Women childbearing potential ( WOCBP ) unwilling unable use acceptable method contraception . Participants receive non approve investigational biologics ( abatacept previous ongoing study Japan ) registration . Participants receive treatment investigational drug within 56 day registration five halflives ( whichever long ) . Participants currently receive treatment leflunomide , mycophenolate mofetil , calcineurine inhibitor cyclosporine tacrolimus , DPenicillamine , Cyclophosphamide , immunoadsorption column . The participant complete Phase II ( IM101071 ) applicable follow instance time registration : active vasculitis , symptom severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , pulmonary , cardiac , neurological , cerebral disease , breast cancer , history cancer within last 5 year , evidence active latent bacterial , viral infection , serious chronic , risk tuberculosis ( TB ) , opportunistic infection , laboratory value hemoglobin &lt; 8.5 g/dL , white blood cell ( WBC ) &lt; 3,000/mm^3 , Platelets &lt; 100,000/mm^3 , Serum creatinine &gt; 2 time upper limit normal ( ULN ) , Serum alanine transaminase aspartate aminotransferase &gt; 2 time ULN .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>